Cart is empty A higher dose and shorter treatment time of a cornerstone tuberculosis (TB) drug has proven to be safe for patients, according to a clinical trial led by researchers at St George’s, University of London. Results have been published in NEJM Evidence.
A higher dose and shorter treatment time of a cornerstone tuberculosis (TB) drug has proven to be safe for patients, according to a clinical trial led by researchers at St George’s, University of London. Results have been published in NEJM Evidence.
Leave A Comment